AMR.Solutions
Menu-01-01

UNGA 2024 and the AMR HLM:
Pre-Meeting Reports and Post-Meeting Notes

The HLM has now happened, but I am going to keep this webpage going (at least for now) as it is useful repository. Helpful post-HLM materials include the following:

  1. The 1 Oct 2024 newsletter for my review of the events at the HLM. And for those who like to listen: Hosted by Cesar Arias, Editor-in-Chief of Antimicrobial Agents and Therapy, John and Prabha Fernandes recorded a podcast discussion of the HLM. 
  2. CDC’s post-UNGA blog post (also available as a .pdf of their nearly identical 4 Oct 2024 post-UNGA summary email). CDC’s summary provides informative highlights from several AMR-related side-meetings. 
  3. WHO’s 4 Oct 2024 AMR email summary. In addition to just being a good tour of WHO’s diverse array of activities, it starts with a quick overview of the HLM and then points to next steps (e.g., the November 2024 Ministerial meeting in Saudi Arabia).
  4. An excellent 9 Oct 2024 blog post from Ramanan Laxminarayan’s One Health Trust that provides a very detailed summaries of several of the side events. Lots of photos, lots of summarized commentary … really gives a good sense of the meetings.
  5. This self-explanatory paper in the November 2024 issue of Open Forum Infectious Diseases: “A Global Call to Action to Fight Antimicrobial Resistance: IDSA and ESCMID Joint White Paper” by Malani, Sharland, Clancy, and Skov on behalf of the IDSA and ESCMID executive boards. https://doi.org/10.1093/ofid/ofae522.
  6. A very thorough 8 Dec 2024 summary of the conversations in and around the HLM: “UN Meeting Highlights Antimicrobial Resistance ‘Epiphany’—Lack of Antibiotic Access Is a Key Driver” by K Schweitzer, JAMA. 2024;332(21):1776-1778. https://doi.org/10.1001/jama.2024.21046.

During the run-up to the HLM (High-Level Meeting) on AMR during UNGA 2024 (the UN General Assembly, September 2024, see the 15 Apr 2023 newsletter for details), I thought it would be useful to have a list of major reports that had been released to inform those discussions. I am sure I am going to miss things (at least initially), so please drop me a note (john.rex@amr.solutions) if you want to see something added to this list. Thanks, —jr

  • Reports (mostly) Focused on AMR related to human health
  • Manufacturing
  • Stewardship and Access
    •  22 Mar 2021: Stewardship & Access Guide
      • From CARB-X, Wellcome, And Partners, this is the definitive guide
      • The 22 Mar 2021 newsletter is the best starting point; it also includes a video chat about the new guidelines
    • Feb 2024: Equitable & Responsible Access Roadmap
  • R&D: Push, Pull, People, and Evidence for Action
    • 07 Sep 2023: Overcoming Resistance
    • 21 Sep 2023: A New Grand Bargain to Improve the Antimicrobial Market for Human Health
      • Tackles the question of “Why would any given group take action to support an antibiotic ecosystem?” from the perspective of High-Income Countries (HICs), Low- and Middle-Income Countries (LMICs), Pharmaceutical companies, and International Organizations.
      • Webpage, report, and 5 Nov 2023 newsletter.
      • Report author: Center for Global Development (CGD)
    • 15 Nov 2023: Value and sustainability of antibiotics as essential tools for the healthcare system and people’s health
    • 08 Feb 2014: Leaving the Lab: Tracking the Decline in AMR R&D Professionals
    • 15 Feb 2024: 2024 AMR Preparedness Index Progress Report
    • 22 Feb 2024: The Economics of Antibiotic Resistance
    • 25 Mar 2024: Effective antibiotics for the Swiss health care system: today and in the future
    • 3 Apr 2024: Towards Specific Commitments and Action in the Response to Antimicrobial Resistance
    • 23 May 2024: The Lancet Series on Antimicrobial Resistance: The need for sustainable access to effective antibiotics
    • 12 Aug 2024: UK Subscription model goes live!
      • OK, it’s not a report per se but if it were it would be called “Here’s what can be done!”
      • The UK Subscription model really does set the pace for the rest of the world to follow
      • Webpage, 19 Aug 2024 newsletter
    • Aug 2024: Antibacterial pipeline trends and recommendations to enhance research and development
      • This policy brief does a good job of briefly (!) outlining 7 key points: the weak pipeline, the issues faced by developers, specific therapeutic gaps, the oral drug gap, the pediatric drug gap, the LMIC gap, and the non-traditional gap
      • Webpage, report, 1 Sep 2024 newsletter
      • Report author: WHO
    • 17 Sep 2024: Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
      •  The team behind the Global Burden of Disease (GBD) project brings us the sobering news that AMR will kill 39m during 2025-2050 unless we act!
      • Link to article and to the 17 Sep 2024 newsletter
      • Report author: GBD 2021 Antimicrobial Resistance Collaborators
    • 27 Sep 2024: Forecasting the Fallout from AMR: Economic Impacts of Antimicrobial Resistance in Humans
      • This paper makes the economic case for action and can be summarized as “Without action, AMR costs go from $66b/yr to $159b/yr by 2050.” The deep economics are not often analyzed — this paper does a great job of articulating the “pay now or pay later” perspective.
      • Article itself and to the 27 Sep 2024 newsletter
      • Report author: Center for Global Development
  • Reports (mostly) focused on agriculture and food chain
  • January 2024: Tackling Antimicrobial Resistance in Food and Agriculture
    • A global survey of actions being taken by the Quadripartite, the Global Leaders Group, and the various National Action Plans on AMR in agricultural and food systems.
    • Webpage, report, and 27 Jan 2024 newsletter.
    • Report author: FAO

During the run-up to UNGA 2024 and the HLM on AMR (15 Apr 2023 newsletter for details), I thought it would be useful to have a list of major reports. I am sure I am going to miss things (at least initially), so please drop me a note (john.rex@13.43.35.2) if you want to see something added to this list.

 

 

Last updated on

Share

More Newsletters

Now live: HERA’s call for rapid point-of-care susceptibility devices

Dear All, I wrote in the 19 Feb 2025 newsletter about HERA’s 13m EUR call for rapid point-of-care susceptibility devices. The call is now live! Title: Development of a Rapid Point-of-care Antimicrobial Susceptibility Testing Diagnostic Medical Device (HADEA/2025/CPN/0006) Funding and Tenders portal link: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/tender-details/2e5c607e-6e55-4268-b99a-730c5db350b7-CN “This call for tenders aims to speed up the development of an in

Updates: CARB-X TPPs; Independent Panel for Evidence for Action against AMR

Dear All, Two quick updates this evening. First, you will recall that CARB-X have announced their initial 2025 funding round (26 Feb 2025 newsletter), with a call for applications for funding of work on (i) small molecules for Gram-negative infection and (ii) diagnostics for typhoid. In support of these calls, TPPs (target product profiles) for both

Unexpected resistance: The tale of rifaximin and daptomycin

Dear All (and with thanks to Patricia Bradford for taking the lead on this newsletter): Today, this paper in Nature takes us on a trip to the land of unintended consequences: Turner, A.M., Li, L., Monk, I.R. et al. Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin. Nature 635, 969–977 (2024). https://doi.org/10.1038/s41586-024-08095-4. A wonkish summary is found below

CARB-X announces its 2025 funding round

Dear All, At BEAM’s AMR Conference in Basel, Team CARB-X have today announced their 2025 funding round. Key points: Two themes: (i) Direct-acting small molecule therapeutics for Gram-negatives (same as in 2024) and (ii) diagnostics for typhoid fever in low-resource settings. 23 Mar 2025 newsletter update: The TPPs for both themes have been released: Small

More Newsletters
Subscribe
Scroll to Top